JANX
JANX
US47103J1051
Janux Therapeutics, Inc.
Loading chart...

Financials

Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
Breakdown 2025 2024 Change %
Total Revenue 10.000.000 10.588.000
5.6%
Cost of Revenue -- --
--
Gross Profit -- --
--
167.667.000 109.435.000
53.2%
Operating Income -157.667.000 -98.847.000
59.5%
Pretax Income -113.625.000 -68.994.000
64.7%
Net Income Common Stockholders -113.625.000 -68.994.000
64.7%
-- --
--
-- --
--
ende